Phase 3 study

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Loxo Oncology, Inc.
Registry number NCT05254743
Started 22 July 2022 Today 16 October 2026 Estimated completion 1 October 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
One Clinical Research Nedlands WA Active not recruiting
Western Health, Sunshine Hospital St Albans VIC Active not recruiting
The Perth Blood Institute West Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 737

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria

* Part 1 - Known 17p deletion status (wildtype or deleted). Part 2 - Must have deletion of 17p as determined by FISH testing

* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

* Adequate organ function

* Platelets greater than or equal to ≥ 50 x 10⁹/liter (L) or ≥30 x 10⁹/L in participants with documented bone marrow involvement considered to impair hematopoiesis,

* Hemoglobin ≥8 grams/deciliter (g/dL) or ≥6 g/dL in participants with documented bone marrow involvement considered to impair hematopoiesis

* Absolute neutrophil count ≥0.75 x 10⁹/L or ≥0.50 × 10⁹/L in participants with documented bone marrow involvement considered to impair hematopoiesis

* Kidney function: Estimated creatinine clearance ≥30 milliliters per minute (mL/min)

Exclusion Criteria:

* Known or suspected Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin's lymphoma at any time preceding enrollment

* Known or suspected central nervous system (CNS) involvement

* A significant history of renal, neurologic, psychiatric, endocrine, metabolic or immunologic disease

* Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \[AIHA\], idiopathic thrombocytopenic purpura \[ITP\])

* Significant cardiovascular disease including ejection fraction \< 40% and any grade ongoing atrial fibrillation or atrial flutter

* Hepatitis B or hepatitis C testing indicating active/ongoing infection, based on Screening laboratory tests

* Active cytomegalovirus (CMV) infection

* Active uncontrolled systemic bacterial, viral, or fungal infection

* Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count

* Clinically significant active malabsorption syndrome or other condition likely to affect GI absorption of the oral-administered study treatments

* Ongoing inflammatory bowel disease

* Previous treatment for CLL/SLL - Part 1: Treatment-naïve and previously treated, except prior exposure to BTK inhibitor (covalent or noncovalent).

Part 2: participants must be treatment naïve

* Concurrent use of investigational agent or anticancer therapy except hormonal therapy

* Participants requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist

* Use of \> 20 mg prednisone daily or equivalent dose of steroid at the time of first dose of study drug

* Vaccination with a live vaccine within 28 days prior to randomization

* Participants receiving chronic therapy with a strong cytochrome P450 (CYP)3A inhibitor (except posaconazole and voriconazole) which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment

* Participants with known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib or ibrutinib

Dates on the record

Started 22 July 2022
Estimated completion 1 October 2027
Registry last updated 17 August 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 17 August 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.